Neumora Therapeutics (NMRA) News Today → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free NMRA Stock Alerts $9.08 -0.69 (-7.06%) (As of 11:16 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineWilliam Blair Brokers Lower Earnings Estimates for Neumora Therapeutics, Inc. (NASDAQ:NMRA)marketbeat.com - May 10 at 8:21 AMNeumora Therapeutics (NASDAQ:NMRA) Posts Earnings Results, Hits Expectationsmarketbeat.com - May 8 at 11:52 AMNeumora Therapeutics, Inc.: Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updatefinanznachrichten.de - May 8 at 10:02 AMNMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024investorplace.com - May 7 at 1:54 PMNeumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updateglobenewswire.com - May 7 at 7:00 AMNeumora Therapeutics to Participate in Upcoming Conferences in Mayfinance.yahoo.com - May 6 at 9:10 AMNeumora Therapeutics (NASDAQ:NMRA) Sees Strong Trading Volumemarketbeat.com - May 2 at 2:26 PMNeumora Therapeutics (NASDAQ:NMRA) Stock Price Up 6.2%marketbeat.com - April 29 at 4:36 PMParkinson’s UK invests £2.1 million in Neumora Therapeutics for preclinical testing of new Parkinson’s drugmsn.com - April 27 at 7:41 AMNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of "Moderate Buy" by Analystsmarketbeat.com - April 27 at 4:12 AMNeumora Therapeutics (NASDAQ:NMRA) Sets New 52-Week Low at $8.98marketbeat.com - April 25 at 3:44 PMWe're Hopeful That Neumora Therapeutics (NASDAQ:NMRA) Will Use Its Cash Wiselyfinance.yahoo.com - April 24 at 1:13 PMNeumora Therapeutics (NASDAQ:NMRA) Trading Down 4.6%marketbeat.com - April 19 at 1:59 PMBiotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Successfinance.yahoo.com - April 18 at 8:41 PMNeumora Therapeutics (NMRA) Price Target Increased by 6.99% to 25.76msn.com - April 17 at 6:31 PMNeumora Therapeutics Becomes Oversold (NMRA)nasdaq.com - April 17 at 1:34 AMNeumora Therapeutics, Inc.: Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Studyfinanznachrichten.de - April 16 at 3:20 PMFDA pauses Watertown biotech’s schizophrenia trialbizjournals.com - April 15 at 2:04 PMNeumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drugfinance.yahoo.com - April 15 at 2:04 PMWhy Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday?finance.yahoo.com - April 15 at 2:04 PMNeumora Therapeutics (NASDAQ:NMRA) Shares Gap Down to $13.56marketbeat.com - April 15 at 12:53 PMNeumora Shares Slide Premarket as FDA Puts Early Study of Schizophrenia Drug on Holdmarketwatch.com - April 15 at 9:04 AMFDA Places Clinical Hold On Neumora's Phase 1 Study Of NMRA-266; Stock Tanks In Pre-Marketmarkets.businessinsider.com - April 15 at 9:04 AMWhy Is Neumora Therapeutics (NMRA) Stock Down 25% Today?investorplace.com - April 15 at 8:45 AMNeumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Studyglobenewswire.com - April 15 at 6:30 AMNeumora Therapeutics (NASDAQ:NMRA) Given Outperform Rating at William Blairmarketbeat.com - April 12 at 11:19 AMNeumora Therapeutics (NASDAQ:NMRA) Trading Down 4.4%marketbeat.com - April 11 at 1:48 PMNeumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Rating of "Moderate Buy" from Brokeragesmarketbeat.com - April 2 at 4:07 AMNeumora Therapeutics (NASDAQ:NMRA) Stock Price Up 4.3%marketbeat.com - April 1 at 3:29 PMNeumora Therapeutics (NASDAQ:NMRA) Receives "Outperform" Rating from Royal Bank of Canadamarketbeat.com - March 28 at 12:33 PMNeumora Therapeutics (NASDAQ:NMRA) Shares Gap Down to $13.21marketbeat.com - March 25 at 1:34 PMNeumora Therapeutics (NASDAQ:NMRA) Trading Down 6.9%marketbeat.com - March 22 at 5:06 PMJPMorgan Chase & Co. Increases Neumora Therapeutics (NASDAQ:NMRA) Price Target to $22.00marketbeat.com - March 18 at 2:53 PMNMRA Apr 2024 17.500 putfinance.yahoo.com - March 16 at 10:27 AMNeumora Therapeutics (NASDAQ:NMRA) Trading 3.6% Higher marketbeat.com - March 14 at 3:16 PMinstitutional investors of Neumora Therapeutics, Inc. (NASDAQ:NMRA) must be disappointed after last week's 20% dropfinance.yahoo.com - March 14 at 9:19 AMNeumora Therapeutics (NASDAQ:NMRA) Shares Gap Down to $17.35marketbeat.com - March 13 at 12:55 PMNeumora Therapeutics to Participate at Stifel 2024 Virtual CNS Daysglobenewswire.com - March 13 at 7:00 AMNeumora Therapeutics (NASDAQ:NMRA) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPSmarketbeat.com - March 8 at 11:54 AMNeumora Therapeutics (NASDAQ:NMRA) Sets New 12-Month High on Earnings Beatmarketbeat.com - March 8 at 10:20 AMNeumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Recommendation of "Moderate Buy" from Analystsmarketbeat.com - March 8 at 3:25 AMNMRA Stock Earnings: Neumora Therapeutics Misses EPS for Q4 2023investorplace.com - March 7 at 5:03 PMNeumora Therapeutics, Inc.: Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updatefinanznachrichten.de - March 7 at 8:01 AMNeumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 7 at 7:00 AMFmr LLC Acquires New Shares in Neumora Therapeutics, Inc. (NASDAQ:NMRA)marketbeat.com - February 28 at 5:29 AMNMRA Feb 2024 12.500 callfinance.yahoo.com - February 15 at 7:58 PMNMRA Feb 2024 15.000 putfinance.yahoo.com - February 15 at 9:57 AMJohnson & Johnson Buys New Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA)marketbeat.com - February 12 at 4:36 PMNeumora Therapeutics (NASDAQ:NMRA) Stock Price Down 2.3%marketbeat.com - February 12 at 1:00 PMNeumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Rating of "Moderate Buy" from Analystsmarketbeat.com - February 12 at 3:23 AM Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. NMRA Media Mentions By Week NMRA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NMRA News Sentiment▼0.390.45▲Average Medical News Sentiment NMRA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NMRA Articles This Week▼62▲NMRA Articles Average Week Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ADMA Biologics News Today 4D Molecular Therapeutics News Today Tarsus Pharmaceuticals News Today Vir Biotechnology News Today Scholar Rock News Today Cullinan Oncology News Today Inhibrx News Today Fusion Pharmaceuticals News Today Autolus Therapeutics News Today Twist Bioscience News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NMRA) was last updated on 5/10/2024 by MarketBeat.com Staff From Our Partners[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICThis 1 Biotech Stock has been shocking the marketsHuge AlertsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward PressTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
